Aastrom to Present at Cowen & Company 27th Annual Health Care Conference
March 09 2007 - 12:00PM
PR Newswire (US)
ANN ARBOR, Mich., March 9 /PRNewswire-FirstCall/ -- Aastrom
Biosciences, Inc. (NASDAQ:ASTM), a company developing cell-based
therapeutics for regenerative medicine, today announced that Gerald
D. Brennan, Jr., Vice President, Administrative & Financial
Operations and Chief Financial Officer will present at the Cowen
& Company 27th Annual Health Care Conference on Wednesday,
March 14, 2007 at 8:00am (EST). The conference will be held March
12-15th at the Boston Marriott Copley Place Hotel in Boston, MA.
(Logo: http://www.newscom.com/cgi-bin/prnh/20070117/CLW099LOGO ) A
live webcast of Aastrom's presentation can be accessed by logging
onto Aastrom's website at http://www.aastrom.com/. A replay of the
presentation will be archived for 2 weeks. About Aastrom
Biosciences, Inc. Aastrom Biosciences, Inc. develops autologous
cell products for the repair or regeneration of multiple human
tissues, based on its proprietary Tissue Repair Cell (TRC)
technology. Aastrom's TRC-based products are a unique cell mixture
containing stem and progenitor cell populations, produced from a
small amount of bone marrow taken from the patient. TRC-based
products have been used in over 240 patients, and are currently in
clinical trials for bone regeneration (osteonecrosis of the femoral
head, long bone fractures and spine fusion) and vascular
regeneration (critical limb ischemia) applications. Aastrom has
reported positive interim clinical trial results for TRCs
suggesting both the clinical safety and the ability of TRCs to
promote healing in bone regeneration applications. The Company is
also developing programs for TRC-based therapies to address cardiac
and neural regeneration indications. TRCs have received Orphan Drug
Designation from the FDA for use in the treatment of osteonecrosis
of the femoral head and the treatment of dilated cardiomyopathy, a
severe chronic disease of the heart. For more information, visit
Aastrom's website at http://www.aastrom.com/. (astmc) This document
contains forward-looking statements, including without limitation,
statements regarding product development objectives, market
development plans, and potential advantages and applications of
Tissue Repair Cells, which involve certain risks and uncertainties.
The forward-looking statements are also identified through use of
the words "plans," and other words of similar meaning. Actual
results may differ significantly from the expectations contained in
the forward-looking statements. Among the factors that may result
in differences are the results obtained from clinical trial
activities, regulatory approval requirements, and the availability
of resources. These and other significant factors are discussed in
greater detail in Aastrom's Annual Report on Form 10-K and other
filings with the Securities and Exchange Commission. CONTACTS: Kris
M. Maly Cameron Associates Investor Relations Department Kevin
McGrath Aastrom Biosciences, Inc. Phone: (212) 245-4577 Phone:
(734) 930-5777 Deanne Eagle (Media) Phone: (212) 554-5463
http://www.newscom.com/cgi-bin/prnh/20070117/CLW099LOGO
http://photoarchive.ap.org/ DATASOURCE: Aastrom Biosciences, Inc.
CONTACT: Kris M. Maly of Aastrom Biosciences, Inc.,
+1-734-930-5777; or Kevin McGrath, +1-212-245-4577, or Deanne
Eagle, +1-212-554-5463, both of Cameron Associates, for Aastrom
Biosciences, Inc. Web site: http://www.aastrom.com/
Copyright
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Sep 2024 to Oct 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Oct 2023 to Oct 2024